Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation

J Hislop, Z Quayyum, A Elders, C Fraser, D Jenkinson, G Mowatt, P Sharma, L Vale, R Petty

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
5 Downloads (Pure)

Abstract

Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.
Original languageEnglish
Pages (from-to)1-178
Number of pages178
JournalHealth Technology Assessment
Volume15
Issue number25
DOIs
Publication statusPublished - 2011

Fingerprint Dive into the research topics of 'Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation'. Together they form a unique fingerprint.

Cite this